Kresmion signals archive
1671 cross-asset signals fired across commodity, crypto, equity, macro. See also the Kresmion brief for 2026-05-30.
crypto (13)
ETH open interest +182.9% - OI surge
SOL open interest +234.0% - OI surge
BTC open interest -37.7% - OI collapse
ETH open interest -62.7% - OI collapse
SOL open interest -59.2% - OI collapse
BTC open interest -36.8% - OI collapse
USDC/USDT has $128.6M volume but only $884K liquidity - thin market, slippage risk
BTC open interest -37.4% - OI collapse
ETH open interest +180.5% - OI surge
SOL open interest +233.8% - OI surge
SOL open interest -59.3% - OI collapse
BTC open interest -48.3% - OI collapse
ETH open interest -62.4% - OI collapse
commodity (8)
OSINT: New Options Activity Replay Tool Launched for Real‑Time Market Insight
OSINT: CBO Warns US Debt Gap to Deepen, Revenues to Lag by 2031
OSINT: Iranian missile strike injures US troops, damages MQ‑9 drones in Kuwait
OSINT: Kazakhstan Volunteers to Accept Iran's Uranium Stockpile, IAEA Says
Oil -1.73% - significant selloff
Gold +1.36% - significant rally
Oil -1.73% - significant selloff
Gold +1.36% - significant rally
equity (179)
FDA approves ALPHAGAN P (AbbVie) - new revenue stream
FDA approves VENCLEXTA (AbbVie) - new revenue stream
FDA approves drug (AbbVie) - new revenue stream
FDA approves ALPHAGAN P (AbbVie) - new revenue stream
FDA approves ALPHAGAN P (AbbVie) - new revenue stream
FDA approves drug (AbbVie) - new revenue stream
FDA approves drug (AbbVie) - new revenue stream
FDA approves drug (PFIZER) - new revenue stream
FDA approves drug (PFIZER) - new revenue stream
FDA approves drug (PFIZER) - new revenue stream
FDA approves drug (PFIZER) - new revenue stream
FDA approves drug (PFIZER) - new revenue stream
FDA approves drug (PFIZER) - new revenue stream
FDA approves drug (PFIZER) - new revenue stream
FDA approves drug (PFIZER) - new revenue stream
FDA approves drug (PFIZER) - new revenue stream
FDA approves drug (PFIZER) - new revenue stream
FDA approves drug (PFIZER) - new revenue stream
FDA approves drug (PFIZER) - new revenue stream
MSFT RSI 71.7 - overbought (crossed above 70)
MSFT RSI 71.7 - overbought (crossed above 70)
Beat consensus by 34.8% - EPS $-0.5 vs $-0.767 estimate
Q1-2026: Missed consensus by 86.7% - EPS $-1.8307890000000002 vs $-0.9806 estimate
Q4-2025: Beat consensus by 220.5% - EPS $0.4 vs $-0.3319 estimate
Q4-2025: Beat consensus by 8.5% - EPS $0.24 vs $0.2213 estimate
Q3-2025: Beat consensus by 31.3% - EPS $0.28 vs $0.2132 estimate
Q1-2026: Beat consensus by 82.8% - EPS $0.23 vs $0.1258 estimate
Q2-2025: Beat consensus by 13.9% - EPS $0.11 vs $0.0966 estimate
Q2-2025: Beat consensus by 10.0% - EPS $0.59 vs $0.5365 estimate
Q4-2025: Beat consensus by 7.4% - EPS $0.49 vs $0.4563 estimate
Missed consensus by 10.8% - EPS $0.47 vs $0.527 estimate
Missed consensus by 5.6% - EPS $2.49 vs $2.637 estimate
Q4-2025: Missed consensus by 32.0% - EPS $-0.9 vs $-0.6818 estimate
Q1-2026: Beat consensus by 40.5% - EPS $-0.43 vs $-0.7222 estimate
Beat consensus by 15.3% - EPS $-0.91 vs $-1.074 estimate
Q3-2025: Beat consensus by 16.4% - EPS $-0.74 vs $-0.8854 estimate
Q1-2026: Missed consensus by 117.3% - EPS $-0.03 vs $0.1734 estimate
Q4-2025: Beat consensus by 264.5% - EPS $0.26 vs $-0.1581 estimate
Q2-2025: Beat consensus by 295.5% - EPS $0.44 vs $-0.2251 estimate
Q2-2025: Beat consensus by 5.1% - EPS $1.64 vs $1.5599 estimate
Beat consensus by 14.3% - EPS $1.16 vs $1.015 estimate
Q1-2026: Missed consensus by 186.7% - EPS $-0.32 vs $-0.1116 estimate
Q2-2025: Beat consensus by 44.2% - EPS $-0.41 vs $-0.7347 estimate
Q3-2025: Beat consensus by 88.6% - EPS $-0.08 vs $-0.7021 estimate
Q1-2026: Missed consensus by 117.5% - EPS $-1.71 vs $-0.7862 estimate
Q4-2025: Beat consensus by 85.4% - EPS $-0.09 vs $-0.6152 estimate
Q1-2026: Beat consensus by 13.9% - EPS $0.12 vs $0.1054 estimate
Q4-2025: Beat consensus by 42.3% - EPS $0.16 vs $0.1124 estimate
Q4-2025: Missed consensus by 260.4% - EPS $-9.59 vs $-2.6613 estimate
Q2-2025: Missed consensus by 146.1% - EPS $-0.38 vs $0.8248 estimate
Q1-2026: Beat consensus by 87.4% - EPS $-0.18 vs $-1.4308 estimate
Q3-2025: Missed consensus by 118.8% - EPS $-2.63 vs $-1.2019 estimate
Q2-2025: Beat consensus by 8.2% - EPS $1.54 vs $1.4227 estimate
Q3-2025: Beat consensus by 6.4% - EPS $1.66 vs $1.5607 estimate
Q4-2025: Missed consensus by 55.4% - EPS $402 vs $902.3548 estimate
Q3-2025: Beat consensus by 34.1% - EPS $1651 vs $1231.5127 estimate
Q1-2026: Missed consensus by 62.6% - EPS $774 vs $2069.9378 estimate
Q2-2025: Beat consensus by 5.9% - EPS $3.95 vs $3.7315 estimate
Q3-2025: Missed consensus by 50.8% - EPS $-0.2 vs $-0.1326 estimate
Q1-2026: Missed consensus by 35.7% - EPS $-0.09 vs $-0.0663 estimate
Q4-2025: Missed consensus by 40.9% - EPS $-0.23 vs $-0.1632 estimate
Missed consensus by 50.3% - EPS $-0.23 vs $-0.153 estimate
Q1-2026: Beat consensus by 13.9% - EPS $0.85 vs $0.7462 estimate
Q4-2025: Missed consensus by 45.4% - EPS $0.47 vs $0.8613 estimate
Q3-2025: Missed consensus by 121.4% - EPS $-0.03 vs $0.1404 estimate
Q4-2025: Missed consensus by 53.4% - EPS $0.05 vs $0.1072 estimate
Q1-2026: Beat consensus by 138.2% - EPS $0.02 vs $-0.0524 estimate
Q4-2025: Beat consensus by 10.0% - EPS $0.16 vs $0.1455 estimate
Q2-2025: Beat consensus by 12.5% - EPS $0.29 vs $0.2577 estimate
Q1-2026: Beat consensus by 24.1% - EPS $0.12 vs $0.0967 estimate
Q3-2025: Beat consensus by 21.3% - EPS $0.24 vs $0.1978 estimate
Q3-2025: Missed consensus by 23.1% - EPS $0.41 vs $0.5329 estimate
Q4-2025: Missed consensus by 76.3% - EPS $0.14 vs $0.5916 estimate
Q1-2026: Beat consensus by 31.8% - EPS $1.02 vs $0.7739 estimate
Q2-2025: Beat consensus by 6.9% - EPS $0.76 vs $0.7112 estimate
Q1-2026: Beat consensus by 6.7% - EPS $2.45 vs $2.2953 estimate
Q4-2025: Missed consensus by 31.3% - EPS $0.97 vs $1.4115 estimate
Q2-2026: Beat consensus by 12.0% - EPS $0.133 vs $0.1188 estimate
Q4-2025: Beat consensus by 20.1% - EPS $0.082 vs $0.0683 estimate
Q4-2024: Missed consensus by 6.2% - EPS $0.109 vs $0.1162 estimate
Q2-2025: Beat consensus by 37.7% - EPS $0.121 vs $0.0879 estimate
Q4-2025: Beat consensus by 33.8% - EPS $0.77 vs $0.5754 estimate
Q2-2025: Missed consensus by 16.6% - EPS $0.652 vs $0.7821 estimate
Beat consensus by 7.6% - EPS $0.652 vs $0.606 estimate
Q3-2025: Beat consensus by 6.4% - EPS $1.54 vs $1.4479 estimate
Q1-2026: Missed consensus by 13.2% - EPS $1.28 vs $1.4754 estimate
Q4-2025: Beat consensus by 22.0% - EPS $1.56 vs $1.2791 estimate
Q4-2025: Beat consensus by 10.8% - EPS $1.66 vs $1.4988 estimate
Q3-2026: Beat consensus by 12.7% - EPS $2.72 vs $2.4132 estimate
Q1-2026: Beat consensus by 11.6% - EPS $1.78 vs $1.5952 estimate
Q2-2026: Beat consensus by 10.0% - EPS $2.13 vs $1.9372 estimate
Q2-2025: Beat consensus by 34.4% - EPS $0.99 vs $0.7368 estimate
Q3-2025: Missed consensus by 18.4% - EPS $0.98 vs $1.2017 estimate
Q4-2025: Missed consensus by 132.3% - EPS $-0.41 vs $1.2703 estimate
Q1-2026: Beat consensus by 62.4% - EPS $0.46 vs $0.2833 estimate
Q2-2025: Beat consensus by 94.5% - EPS $0.33 vs $0.1697 estimate
Q1-2026: Missed consensus by 92.2% - EPS $0.02 vs $0.2563 estimate
Q3-2025: Missed consensus by 20.6% - EPS $0.17 vs $0.2141 estimate
Q4-2025: Beat consensus by 29.1% - EPS $0.25 vs $0.1937 estimate
Q4-2025: Missed consensus by 13.2% - EPS $3.4 vs $3.9171 estimate
Beat consensus by 19.9% - EPS $3.37 vs $2.81 estimate
Q1-2026: Beat consensus by 28.5% - EPS $-0.07 vs $-0.0979 estimate
Q2-2025: Beat consensus by 81.0% - EPS $-0.03 vs $-0.1577 estimate
Q4-2025: Missed consensus by 1425.5% - EPS $-2.36 vs $-0.1547 estimate
Q3-2025: Beat consensus by 28.6% - EPS $-0.09 vs $-0.1261 estimate
Q2-2025: Beat consensus by 5.3% - EPS $1.52 vs $1.4432 estimate
Q3-2025: Missed consensus by 82.3% - EPS $0.05 vs $0.2825 estimate
Q4-2025: Beat consensus by 172.9% - EPS $0.17 vs $0.0623 estimate
Beat consensus by 398.6% - EPS $0.63 vs $-0.211 estimate
Q1-2026: Beat consensus by 30.0% - EPS $-0.05 vs $-0.0714 estimate
Beat consensus by 17.6% - EPS $0.54 vs $0.459 estimate
Q1-2026: Beat consensus by 7.8% - EPS $0.42 vs $0.3897 estimate
Q2-2025: Beat consensus by 6.3% - EPS $0.36 vs $0.3386 estimate
Q4-2025: Missed consensus by 9.5% - EPS $0.36 vs $0.3978 estimate
Q1-2026: Beat consensus by 44.0% - EPS $-0.08 vs $-0.1428 estimate
Q1-2026: Missed consensus by 12.0% - EPS $-0.16 vs $-0.1428 estimate
Q4-2025: Beat consensus by 19.3% - EPS $-0.14 vs $-0.1734 estimate
Q2-2025: Missed consensus by 81.0% - EPS $-0.24 vs $-0.1326 estimate
Q4-2025: Missed consensus by 11.4% - EPS $-0.92 vs $-0.8262 estimate
Beat consensus by 98.0% - EPS $-0.001 vs $-0.051 estimate
Beat consensus by 40.4% - EPS $-13.5 vs $-22.644 estimate
Beat consensus by 34.6% - EPS $-0.4 vs $-0.612 estimate
Q1-2026: Beat consensus by 14.4% - EPS $2.7 vs $2.3597 estimate
Beat consensus by 5.1% - EPS $3.4 vs $3.236 estimate
Q2-2025: Beat consensus by 5.3% - EPS $0.68 vs $0.6459 estimate
Beat consensus by 8.6% - EPS $0.83 vs $0.764 estimate
Q1-2026: Missed consensus by 14.9% - EPS $0.66 vs $0.7752 estimate
Q3-2025: Beat consensus by 18.2% - EPS $0.56 vs $0.4738 estimate
Missed consensus by 239.6% - EPS $-0.18 vs $-0.053 estimate
Missed consensus by 115.7% - EPS $-0.11 vs $-0.051 estimate
Q3-2025: Beat consensus by 8.2% - EPS $2.28 vs $2.1069 estimate
Q4-2025: Beat consensus by 6.9% - EPS $2.59 vs $2.4227 estimate
Q1-2026: Beat consensus by 29.6% - EPS $-0.36 vs $-0.5115 estimate
Q3-2025: Missed consensus by 138.4% - EPS $-0.33 vs $-0.1384 estimate
Missed consensus by 267.3% - EPS $-1.2341 vs $-0.336 estimate
Q1-2026: Beat consensus by 8.9% - EPS $7.23 vs $6.6406 estimate
Q2-2025: Missed consensus by 9.9% - EPS $4.08 vs $4.5292 estimate
Q1-2026: Beat consensus by 32.5% - EPS $0.56 vs $0.4226 estimate
Q3-2025: Beat consensus by 101.9% - EPS $0.44 vs $0.2179 estimate
Q4-2025: Beat consensus by 42.2% - EPS $-0.11 vs $-0.1904 estimate
Q2-2026: Beat consensus by 20.1% - EPS $0.62 vs $0.5161 estimate
Q4-2025: Beat consensus by 6.3% - EPS $2.28 vs $2.1446 estimate
Q1-2026: Missed consensus by 11.3% - EPS $-0.54 vs $-0.4852 estimate
Q4-2025: Missed consensus by 69.6% - EPS $-0.819 vs $-0.4828 estimate
Q2-2025: Beat consensus by 31.1% - EPS $-0.52 vs $-0.7548 estimate
Q3-2025: Beat consensus by 41.9% - EPS $-0.33 vs $-0.5678 estimate
Q2-2025: Missed consensus by 20.7% - EPS $0.71 vs $0.8958 estimate
Q4-2025: Missed consensus by 5.9% - EPS $0.798 vs $0.8478 estimate
Q3-2025: Beat consensus by 50.7% - EPS $1.19 vs $0.7895 estimate
Q1-2026: Beat consensus by 48.7% - EPS $1.29 vs $0.8678 estimate
Q3-2025: Missed consensus by 5.5% - EPS $2.36 vs $2.4984 estimate
Q1-2026: Beat consensus by 17.3% - EPS $3.35 vs $2.8565 estimate
Q2-2025: Beat consensus by 15.4% - EPS $2.82 vs $2.4433 estimate
Q4-2025: Beat consensus by 5.2% - EPS $2.74 vs $2.6039 estimate
Q4-2025: Missed consensus by 60.3% - EPS $-0.29 vs $-0.1809 estimate
Q2-2025: Missed consensus by 318.3% - EPS $-0.32 vs $-0.0765 estimate
Q3-2025: Missed consensus by 205.6% - EPS $-0.14 vs $0.1326 estimate
Q1-2026: Beat consensus by 50.9% - EPS $0.21 vs $0.1392 estimate
Q2-2026: Beat consensus by 11.8% - EPS $5.79 vs $5.1798 estimate
Q3-2026: Beat consensus by 8.7% - EPS $5.14 vs $4.7306 estimate
Q1-2026: Beat consensus by 13.5% - EPS $6.72 vs $5.9221 estimate
Q3-2025: Beat consensus by 18.6% - EPS $0.56 vs $0.4722 estimate
Q1-2026: Beat consensus by 20.1% - EPS $0.5 vs $0.4163 estimate
Q4-2025: Beat consensus by 16.6% - EPS $0.53 vs $0.4545 estimate
Q1-2026: Missed consensus by 243.0% - EPS $-0.13 vs $0.0909 estimate
Q3-2025: Beat consensus by 37.5% - EPS $0.25 vs $0.1818 estimate
Q2-2025: Missed consensus by 6.8% - EPS $0.32 vs $0.3434 estimate
Q4-2025: Beat consensus by 377.2% - EPS $0.14 vs $-0.0505 estimate
Q3-2025: Beat consensus by 5.9% - EPS $-0.34 vs $-0.3615 estimate
Q4-2025: Beat consensus by 92.3% - EPS $0.23 vs $0.1196 estimate
Q1-2026: Beat consensus by 18.7% - EPS $-0.3 vs $-0.3692 estimate
Q2-2025: Missed consensus by 19.7% - EPS $-0.31 vs $-0.2589 estimate
Q2-2025: Missed consensus by 51.0% - EPS $0.07 vs $0.1428 estimate
Q1-2026: Missed consensus by 118.4% - EPS $-0.03 vs $0.1632 estimate
Q3-2025: Missed consensus by 131.2% - EPS $-0.07 vs $0.2244 estimate
Q4-2025: Missed consensus by 56.4% - EPS $0.12 vs $0.2754 estimate
Q4-2009: Missed consensus by 7.2% - EPS $0.32155 vs $0.3465 estimate
Q2-2025: Beat consensus by 166.0% - EPS $0.19 vs $-0.2879 estimate
Q1-2026: Beat consensus by 54.9% - EPS $-0.14 vs $-0.3106 estimate